StableStock 🐳(@StableStock):Eli Lilly $LLY is strengthening its lead in the obesity drug race. 💊📈 Q3 revenue surged 39% YoY to $24.4B, driven by Mounjaro and Zepbound, prompting the company to raise its full-year outlook. Meanwhile, new Phase 3 Retatrutide data showed around 20–21% average weight loss at week 80, reinforcing Lilly's position in the GLP-1 market. With another $5B committed to U.S. manufacturing, Lilly is scaling up for the next phase of growth. $LLY is available to trade on StableStock: https://t.co/sP3kdQRosY For informational purposes only. Not investment advice.

2026.10.30 11:00

Eli Lilly $LLY is strengthening its lead in the obesity drug race. 💊📈 Q3 revenue surged 39% YoY to $24.4B, driven by Mounjaro and Zepbound, prompting the company to raise its full-year outlook. Meanwhile, new Phase 3 Retatrutide data showed around 20–21% average weight loss at week 80, reinforcing Lilly's position in the GLP-1 market. With another $5B committed to U.S. manufacturing, Lilly is scaling up for the next phase of growth. $LLY is available to trade on StableStock: For informational purposes only. Not investment advice.